NYSEAMERICAN:MAIA MAIA Biotechnology Q4 2025 Earnings Results & Report $1.12 0.00 (0.00%) Closing price 04:10 PM EasternExtended Trading$1.13 +0.01 (+0.89%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MAIA Biotechnology beat analyst earnings expectations in its Q4 2025 results, released March 23, 2026. The company reported EPS of -$0.08 versus the -$0.13 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ4 2025Report DateMarch 23, 2026TimeBefore Market OpensConference Call7:00 AM ET MAIA Biotechnology EPS ResultsActual EPS-$0.08Consensus EPS -$0.13Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMAIA Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMAIA Biotechnology's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) MAIA Biotechnology Q4 2025 Earnings FAQ Did MAIA Biotechnology beat earnings estimates for Q4 2025? MAIA Biotechnology (NYSEAMERICAN:MAIA) reported earnings of -$0.08 per share for Q4 2025, beating the consensus estimate of -$0.13. The report was announced on Monday, March 23, 2026. When is MAIA Biotechnology's next earnings date? MAIA Biotechnology's next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for MAIA Biotechnology on the company's earnings history page. MAIA Biotechnology Earnings HeadlinesMAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%October 7, 2026 | rttnews.comMAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerOctober 7, 2026 | globenewswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 15 at 1:00 AM | Weiss Ratings (Ad)MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Jumps 0.8% - What's Next?October 7, 2026 | americanbankingnews.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)October 1, 2026 | globenewswire.comMAIA Biotechnology, Inc. berichtet über Fortschritte in der zulassungsrelevanten Phase-3-Studie bei fortgeschrittenem nicht-kleinzelligem LungenkrebsSeptember 23, 2026 | de.marketscreener.comDSee More MAIA Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email. Email Address About MAIA BiotechnologyMAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research is centered on telomere biology, an area that seeks to exploit the mechanisms cancer cells use to maintain their ability to divide and survive. MAIA’s lead investigational product is atebimetostat, also known as THIO or 6-thio-2’-deoxyguanosine. The small-molecule therapy is designed to induce telomere dysfunction and promote the death of cancer cells. The company has evaluated atebimetostat in clinical studies involving patients with advanced non-small cell lung cancer, including research exploring its use following treatment with immune checkpoint inhibitors and in combination with immunotherapy. MAIA Biotechnology was founded in 2018 and is headquartered in Chicago, Illinois. The company has been led by co-founder Vladislav Sandler, who serves as chief executive officer. Its development activities are focused primarily on advancing atebimetostat and related telomere-targeting approaches for patients with difficult-to-treat solid tumors.View MAIA Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
